Alle Meldungen
Abonnieren Sie alle Meldungen von Solianis Monitoring AG

08.02.2010 – 08:47

Solianis Monitoring AG

Solianis Monitoring AG on its Way to Success - Market Entry as Planned in 2011

    Zurich (ots)

Solianis Monitoring AG presents its Non-Invasive, Continuous Glucose Monitoring System at the 3rd International Conference on Advanced Technologies and Treatments for Diabetes (Basel, Switzerland, February 10-13, 2010).

    Dr. Andreas Caduff, PhD, Chief Technology Officer of Solianis,      
will present the concept of Solianis' proprietary Multisensor        
Glucose Monitoring System (MGMS) which in first tests under daily use
conditions performed according expectations.

    "We are pleased with this progress" says Mario Stark, CEO of        
Solianis. "Currently we are setting up manufacturing and will        
subject our final prototype to rigorous clinical tests. These        
tests are the prerequisite to obtain CE approval for market entry in
Europe in 2011. They will also give us the assurance that our MGMS is
safe and provides people with diabetes with the information they and
their healthcare professionals need. As an organization, we are
expanding from a start-up enterprise towards a company which takes
the responsibility to bring a reliable MGMS to market. Our ongoing
interaction with scientific and clinical experts as well as patient
groups ensures that MGMS becomes a system that meets the day-to-day
needs of people with diabetes, their relatives and healthcare

    Solianis Monitoring AG is a Swiss medical device company        
developing an innovative non-invasive Continuous Glucose        
Monitoring (CGM) system for people with diabetes, their relatives and
health care professionals. Its unique and proprietary technology is
integrated in a Multisensor Glucose Monitoring System (MGMS) which
continuously delivers information on glucose variations comparable to
the minimally invasive devices currently approved by the FDA.

    Solianis was incorporated in May 2005 and has so far been funded  
by private investors, the Pioneer Fond of the Zurich Cantonal        
Bank and the EGS Beteiligungen AG. Solianis plans to introduce        
its first product for insulin dependent patients with diabetes in
Europe in 2011, after product registration.

ots Originaltext: Solianis Monitoring AG

Micaela Wochner        
Tel.:        +41/44/306'80'29        
Mobile:    +41/79/431'79'34        

Mario Stark        
Tel.:    +41/44/306'80'40        
Mobile: +41/79/542'88'74        

Weitere Meldungen: Solianis Monitoring AG

Weitere Meldungen: Solianis Monitoring AG